Site Profile & Oversight Tool (SPOT) and Intelligent
Medical Coding (IMC) unveiled by RBQM innovator at DIA Global
Annual Meeting 2024
KING OF PRUSSIA, Pa.,
June 17, 2024 /PRNewswire/
-- CluePoints, provider of leading statistical and AI-driven
software solutions, will unveil two of its latest advanced, deep
learning technology innovations at the DIA Global Annual Meeting
2024. Both solutions deliver groundbreaking enterprise platform
transformations providing Sponsors and CROs with a smarter way to
conduct clinical research and detect and manage risks that could
impact clinical trial outcomes.
Taking RBQM to a new level, CluePoints' Site Profile &
Oversight Tool (SPOT) delivers adaptive
site monitoring, enabling teams to swiftly pinpoint anomalies and
translate insights into strategies and actions. Sponsors and CROs
can improve their ability to evaluate the performance of clinical
trial sites and adjust site visit plans more effectively and
efficiently while accurately balancing risk and resource
workload.
Further streamlining processes, CluePoints' Intelligent
Medical Coding solution harnesses advanced deep learning
technology to enhance the accuracy and efficiency of coding in
clinical trials. It seamlessly integrates with existing systems to
offer precise, AI-generated coding suggestions, drastically
reducing the need for manual dictionary searches and costly coding
reviews, freeing up valuable resources and ensuring uniformity
across all coded data.
Andy Cooper, CEO of CluePoints,
said: "DIA offers the perfect opportunity to share with the
industry our latest disruptive and innovative solutions that
address key challenges within traditional clinical research
methods. Unveiling two new products that leverage next generation
AI will transform how CluePoints is viewed in the industry, as we
enhance our enterprise-wide solutions to reach new levels of
accuracy and efficiency to both improve clinical trial performance
and deliver greater insights to further mitigate risk. Our early
adopters are already raving about how valuable they are finding
both product offerings and we are excited to showcase how they will
shape future processes and embody our brand promise to
'turn artificial intelligence into human intelligence."
With over 9,500 users engaged with CluePoints' enterprise
platform, to date over 1,600 studies have been de-risked and over
142,000 issues detected.
Visitors to the CluePoints' DIA Global exhibition booth #1301
will have the opportunity to meet with subject matter experts and
see demonstrations of both new platform solutions.
CluePoints also invites DIA attendees to join them at 3pm on
Tuesday, June 18th, for a
special toast at their booth to celebrate the latest innovations.
To learn more about CluePoints' award-winning solutions, please
visit www.cluepoints.com.
About CluePoints
CluePoints is the premier Risk-Based Quality
Management (RBQM) and Data Quality Oversight Software
provider. We are leveraging the potential of artificial
intelligence using advanced statistics and machine learning to
determine the quality, accuracy, and integrity of clinical
trial data both during and after study conduct. Aligned with
guidance from the FDA, EMA, and ICH E6 (R2), CluePoints is
deployed to support central and on-site monitoring, medical
review, quality risk management and to drive a holistic
Risk-Based strategy in all trials. Coupled with thought
leadership and consulting expertise to aid pre-study risk
assessment, identification of risk controls and
solution implementation, you now have everything you need to
adhere with global regulatory guidance. The result is positive
clinical development outcomes, increased operational
efficiency, lower costs and reduced regulatory submission risk
as part of the industry paradigm shift to RBQM.
View original
content:https://www.prnewswire.co.uk/news-releases/cluepoints-continues-turning-artificial-intelligence-into-human-intelligence-by-launching-two-new-innovations-302174137.html